Published online October 2, 2006
PEDIATRICS Vol. 118 No. 4 October 2006, pp. 1422-1430 (doi:10.1542/peds.2006-0678)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by LeBaron, C. W.
Right arrow Articles by Gargiullo, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by LeBaron, C. W.
Right arrow Articles by Gargiullo, P.
Related Collections
Right arrow Infectious Disease & Immunity
Right arrowRelated AAP Red Book topics:
Rubella
Measles
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

ARTICLE

Evaluation of Potentially Common Adverse Events Associated With the First and Second Doses of Measles-Mumps-Rubella Vaccine

Charles W. LeBaron, MDa, Daoling Bi, MSa, Bradley J. Sullivan, PhD, MDb, Carol Beck, BAb and Paul Gargiullo, PhDa

a Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
b Marshfield Medical Research Foundation, Marshfield, Wisconsin

BACKGROUND/OBJECTIVES. In 1989, the American Academy of Pediatrics and the Advisory Committee on Immunization Practices recommended that school children receive 2 doses of measles-mumps-rubella vaccine. With measles and rubella eliminated from the United States, measles-mumps-rubella vaccine adverse events have come under scrutiny, but no study has compared the reactogenicity of the first (measles-mumps-rubella vaccine dose 1) and second (measles-mumps-rubella vaccine dose 2) doses at the most common ages of administration in the United States.

METHODS. From a health maintenance organization, 3 groups of children were recruited: (1) toddlers aged 12 to 24 months receiving measles-mumps-rubella vaccine dose 1; (2) kindergartners aged 4 to 6 years receiving measles-mumps-rubella vaccine dose 2; and (3) middle schoolers aged 10 to 12 years receiving measles-mumps-rubella vaccine dose 2. From 2 weeks before measles-mumps-rubella vaccine administration until 4 weeks afterward, families recorded in diaries the occurrence of potentially common symptoms. Postvaccination symptom rates were compared with the prevaccination baseline, with significance assessed by testing incidence rate ratios estimated by Poisson regression.

RESULTS. Of 2173 children enrolled, 373 (17%) were lost to attrition, producing a study population of 1800. Compared with the prevaccination baseline, rates of fever, diarrhea, and rash were significantly elevated postvaccination among 535 toddlers receiving measles-mumps-rubella vaccine dose 1. An estimated net 95 (18%) experienced measles-mumps-rubella vaccine-associated events (median onset 5–10 days postvaccination, duration 2–5 days), with high fever (temperature ≥39.5°C) occurring in 33 (6%). None required medical attention. For 633 kindergartners and 632 middle schoolers, symptom rates were not significantly elevated after measles-mumps-rubella vaccine dose 2 compared with baseline.

CONCLUSIONS. Vaccination-associated adverse events occur in ~1 of every 6 toddlers receiving measles-mumps-rubella vaccine dose 1, with high fever occurring in 1 of 20. Adverse events are infrequent for measles-mumps-rubella vaccine dose 2 administered to school-aged children.

Key Words: measles • mumps • and rubella vaccine • adverse reactions • second dose • dose schedule

Abbreviations: ACIP—Advisory Committee on Immunization Practices • AAP—American Academy of Pediatrics • MMR—measles-mumps-rubella vaccine • CDC—Centers for Disease Control and Prevention • MMR1—first dose of measles-mumps-rubella vaccine • MMR2—second dose of measles-mumps-rubella vaccine

Accepted May 24, 2006.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Arch Pediatr Adolesc MedHome page
C. W. LeBaron, J. Beeler, B. J. Sullivan, B. Forghani, D. Bi, C. Beck, S. Audet, and P. Gargiullo
Persistence of Measles Antibodies After 2 Doses of Measles Vaccine in a Postelimination Environment
Arch Pediatr Adolesc Med, March 1, 2007; 161(3): 294 - 301.
[Abstract] [Full Text] [PDF]

Home page
 JWatch GeneralHome page
Reactions to a Second Dose of MMR Vaccine
Journal Watch (General), October 26, 2006; 2006(1026): 2 - 2.
[Full Text]

Home page
 JWatch PediatricsHome page
Reactions to a Second Dose of MMR Vaccine
Journal Watch Pediatrics and Adolescent Medicine, October 25, 2006; 2006(1025): 2 - 2.
[Full Text]